Augmentation of IL-2 activated natural killer cell adoptive immunotherapy with cyclophosphamide

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1441-1446

  Goldfarb, Ronald H ^a,d   Ohashi, Masami ^a,b   Brunson, Kenneth W ^a   Kirii, Yasuyuki ^a,b   Kotera, Yasuo ^a,b   Basse, Per H ^a,c   Kitsn, Richard P ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b KANEBO LTD   (Japan)

^c AARHUS UNIVERSITY   (Denmark)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

Adoptive immunotherapy; Cyclophosphamide; NK cells

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 2; MACROGOL;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; LEWIS CARCINOMA; LUNG METASTASIS; MELANOMA B16; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL;

ADOPTIVE TRANSFER; ANIMALS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS;

EID: 0031854672     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Lafreniere R, Rosenberg SA: Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Res 45: 3735-3741, 1985.
2. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Scripp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 888-897, 1987.
3. Goldfarb RH, Brunson KW: Antimetastatic therapy. In: Biological Therapy of Cancer. Second Edition (DeVita VTJ, Hellman S, Rosenberg SA, eds). Philadelphia, PA., J.B. Lippincott and Company, 1995, pp 853-861.
4. Goldfarb RH, Brunson KW: Therapeutic agents for treatment of established metastases and inhihitors of metastatic spread: preclinical and clinical progress. Curr Opin Oncol 4: 1130-1141, 1992.
5. Goldfarb RH, Kitson RP, Brunson KW: Biology of cancer metastases. In: Regional Therapy of Advanced Cancer (Lotze MT, Ruhin JT, eds)., J.B. Lippincott Co., 1997, pp 1-9.
6. Goldfarb RH, Whiteside TL, Basse PH, Lin WC, Vujanovic N, Herberman RB: Natural killer cells and gene therapy: potential of gene transfection for optimizing effector cell functions and for targeting gene products into tumor metastases. Nat Immun 13: 131-140, 1994.
7. Herberman RB, Basse P, Jain RK, Melder RJ, Goldfarb RH, Gorelik E, Ernstoff MS, Kirkwood JM, Whiteside TL: Approaches to immunotherapy with defined populations of IL-2 cultured NK cells, immune T cells, or tumour infiltrating lymphocytes. In: The Biology and Clinical Applications of lnterleukin-2 (Rees RC, ed.) Oxford, IRL Press, 1990, pp 111-119.
8. Whiteside TL, Goldfarb RH: Antitumor effector cells: Extravasation and control of metastasis. In: Tumor Immunology and Cancer Therapy (Goldfarb RH, Whiteside TL, eds). New York, Marcel Dekker, Inc., 1994, pp 159-173.
9. Mazumder A, Rosenberg SA: Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2. J Exp Med 159: 495-507, 1984.
10. Mule JJ, Shu S, Schwarz SL, Rosenberg SA: Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 225: 1487-1489, 1984.
11. Schoof DD, Gramolini BA, Davidson DL, Massaro AF, Wilson RE, Eberlein TJ: Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells. Cancer Res 48: 5007-5010, 1988.
12. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK: Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898-905, 1987.
13. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH, White DE: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907-913, 1994.
14. Vujanovic NL, Herberman RB, Al Maghazachi A, Hiserodt JC: Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells. J Exp Med 167: 15-29, 1988.
15. Schwarz RE, Vujanovic NL, Hiserodt JC: Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Cancer Res 49: 1441-1446, 1989.
16. Yasumura S, Lin WC, Hirabayashi H, Vujanovic NL, Herberman RB, Whiteside TL: Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells. Cancer Res 54: 3808-3816, 1994.
17. Vujanovic NL, Yasumura S, Hirabayashi H, Lin WC, Watkins S, Herberman RB, Whiteside TL: Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues. J Immunol 154: 281-289, 1995.
18. Basse P, Herberman RB, Nannmak U, Johansson BR, Hokland M, Wasserman K, Goldfarb RH: Accumulation of adoptively transferred adherent, lymphokine-activated killer cells in murine metastases. J Exp Med 174: 479-488, 1991.
19. Basse PH, Nannmark U, Johansson BR, Herberman RB, Goldfarb RH: Establishment of cell-to-cell contact by adoptively transferred adherent lymphokine-activated killer cells with metastatic murine melanoma cells. J Natl Cancer Inst 83: 944-950, 1991.
20. Basse PH, Goldfarb RH. Herberman RB, Hokland ME: Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2. In Vivo 8: 17-24, 1994.
21. Nannmark U, Johansson BR, Bryant JL, Unger ML, Hokland ME, Goldfarb RH, Basse PH: Microvessel origin and distribution in pulmonary metastases of B16 melanoma: implication for adoptive immunotherapy. Cancer Res 55: 4627-4632, 1995.
22. Salup RR, Wiltrout RH: Adjuvant immunotherapy of established murine renal cancer by interleukin 2-stimulated cytotoxic lymphocytes. Cancer Res 46: 3358-3363, 1986.
23. Kedar E, Ben-Aziz R, Epstein E, Leshem B: Chemo-immunotherapy of murine tumors using interleukin-2 (IL-2) and cyclophosphamide. IL-2 can facilitate or inhibit tumor growth depending on the sequence of treatment and the tumor type. Cancer Immunol Immunother 29: 74-78, 1989.
24. Gazit Z, Weiss DW, Shouval D, Yechezkeli M, Schirrmacher V, Notter M, Walter J, Kedar E: Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines. Cancer Immunol Immunother 35: 135-144, 1992.
25. Kedar E, Klein E: Cancer immunotherapy: are the results discouraging? Can they be improved? Adv Cancer Res 59: 245-322, 1992.
26. Eggermont AM, Sugarbaker PH: Efficacy of chemoimmunotherapy with cyclophosphamide, interleukin-2 and lymphokine activated killer cells in an intraperitoneal murine tumour model. Br J Cancer 58: 410-414, 1988.
27. Kawata A, Une Y, Hosokawa M, Wakizaka Y, Namieno T, Uchino J, Kobayashi H: Adjuvant chemoimmunotherapy for hepatocellular carcinoma patients. Adriamycin, interleukin-2. and lymphokine-activated killer cells versus adriamycin alone. Am J Clin Oncol 18: 257-262. 1995.
28. Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E: Generation and characterization of purified adherent lymphokine-activated killer cells in mice. J Immunol 142: 1748-1754, 1989.
29. Basse PH, Goldfarb RH: Localization of immune effector cells to tumor metastases. In: Tumor Immunology and Cancer Therapy (Goldfarb RH, Whiteside TL, eds). New York, Marcel Dekker, Inc.. 1994, pp 149-158.
30. Knauf MJ, Bell DP, Hirtzer DP, Luo Z-P, Young JD, Katre NV: Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem 263: 15064-15070, 1988.
31. Laude M, Siessmann KL, Mokyr MB, Dray S: Advantages of adoptive chemoimmunotherapy with polyethylene glycol-cultured, antigen-activated, tumor-infiltrated spleen cells for the complete eradication of lethal MOPC-315 plasmacytomas. Cancer Res 51: 4516-4522, 1991.
32. Rawata A, Hosokawa M, Sawamura Y, Ito K, Une Y, Shibata T, Uchino J, Kobayashi H: Modification of lymphokine-activated killer cell accumulation into tumor sites by chemotherapy, local irradiation. or splenectomy. Molecular Biotherapy 2: 221-227, 1990.
33. Hosokawa M. Wakizaka Y, Kuramitsu Y, Micallef M, Togashi Y, Kobayashi H: Augmented accumulation of transferred lymphokine-activated killer (LAK) cells at murine tumor sites through production of LAK-attractant facilitated by chemotherapy. Tohoku J Exp Med 768: 413-416, 1992.
34. Laude M, Russo KL, Mokyr MB, Dray S: Cure of mice bearing a late-stage, highly metastatic, drug-resistant tumor by adoptive chemoimmunotherapy. Cancer Immunol Immunother 36: 229-236, 1993.
35. Gold JE, Zachary DT, Osband ME: Adoptively transferred ex vivo activated memory T cells with cyclophosphamide: effective tumorspecific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma. Clin Immunol Immunopathol 73: 115-122, 1994.
36. Gazit Z, Kedar E: Chemotherapy-induced modulation of natural killer and lymphokine-activaled killer cell activity in euthymic and athymic mice. Cancer Immunol Immunother 38: 243-252, 1994.
37. North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155: 1063-1074, 1982.
38. Ballas ZK: Lymphokine-activated killer (LAK) cells. 1. Differential recovery of LAK, natural killer cells, and cytotoxic T lymphocytes after a sublethal dose of cyclophosphamide. J Immunol 137: 2380-2384, 1986.